Table 2.
Latest information on COVID-19 vaccines with approvals and phase 3 clinical trial results.
| Developer country | Developer | Vaccine name | Strategy | Regimen | Efficacy | Storage | Countries approvals | Latest publication |
|---|---|---|---|---|---|---|---|---|
| United States and Germany | Pfizer-Biotech | BNT162b2 | mRNA | Two-dose | 95 % | −80 to -60 °C | 79 approvals (US, UK, EU, AR, AU, others) | Polack et al., 2020 |
| United States and Germany | Janssen | Ad26.COV2.S | Ad26 | One-dose | 74.4 % (US), 64.7 % (LatAm), 52.0 % (ZA) | 2 to 8 °C | 35 approvals (US, EU, CA, ZA, others) | Oliver et al., 2021 |
| United States | Moderna | mRNA-1273 | mRNA | Two-dose | 94.0 % | −25 to -15 °C | 41 approvals (US, UK, EU, IL, others) | Baden et al., 2021 |
| United Kingdom and Sweden | Oxford-AstraZeneca | AZD-1222 | ChAdOx1 | Two-dose | 70.4 % | 2 to 8 °C | 81 approvals (UK, EU, BR, IN, MA, others) | Voysey et al., 2021 |
| Russia | Gamaleya | Sputnik-V | Ad26, Ad5 | Two-dose | 91.6 % | −18 °C | 55 approvals (RU, AR, AE, GN, others) | Logunov et al., 2021 |
| China | CanSino | Ad5-nCoV (Convidecia) |
Ad5 | One-dose | NA | NA | 4 approvals (CN, HU, MX, PK) | Zhu et al., 2020 |
| China | Sinopharm | BBIBP-CorV | Inactivated | Two-dose | NA | 2 to 8 °C | 27 approvals (BH, EG, HU, IQ, PE, CS, AE, others) | Xia et al., 2021 |
| China | Sinovac | CoronaVac | Inactivated | Two-dose | 50.4 % | 2 to 8 °C | 19 approvals (BR, CL, CN, ID, TR, others) | Zhang et al., 2021 |
| India | Bharat Biotech | BBV152 (Covaxin) | Inactivated | Two-dose | NA | 2 to 8 °C | 5 approvals (IN, IR, MA, NP, ZW) | Ella et al., 2021 |
AR: Argentina; AE: United Arab Emirates; AU: Australia; BH: Bahrain; BR: Brazil; CA: Canada; CL: Chile; CN: China; EG: Egypt; EU: European Union; GN: Guinea; HU: Hungary; ID: Indonesia; IL: Israel; IN: India; IR: Iran; IQ: Iraq; LatAm: Latin American; MA: Morocco; MA: Mauritius; MX: Mexico; NP: Nepal; PE: Peru; PK: Pakistan; RU: Russia; TR: Turkey; UK: United Kingdom; CS: Republic of Serbia; ZA: South Africa; ZW: Zimbabwe; LatAm: Latin America.
NA: Not available.